- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on FCER2 Negative
Total 3371 results
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | CD20 Positive | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | CCND1 Protein Overexpression | CD5 Positive | FCER2 Negative | Pleomorphic Variant Mantle Cell Lymphoma | t(11;14)(q13;q32)United States
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.CompletedEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple -Negative Breast Cancer | Anatomic Stage IV Breast Cancer AJCCUnited States
-
University of WashingtonTerminatedEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7United States
-
OncoSec Medical IncorporatedCompletedER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
Massachusetts General HospitalGilead SciencesRecruitingTriple Negative Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast CancerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Prospect Creek FoundationCompletedAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Syndax PharmaceuticalsTerminatedBreast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor PositiveUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
SanofiUNC Lineberger Comprehensive Cancer CenterCompletedBrain Metastases | Estrogen Receptor Negative (ER-Negative) Breast Cancer | Progesterone Receptor Negative (PR-Negative) Breast Cancer | Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast CancerUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Triple-negative Breast Carcinoma | Progesterone Receptor-negativeUnited States
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Loma Linda UniversityWithdrawnNegative Dysphotopsia
-
National Cancer Institute (NCI)GlaxoSmithKlineCompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
Merrimack PharmaceuticalsSanofiCompletedER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer PatientsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Seoul National University HospitalCompletedMultidrug-resistant Gram-negative Bacteria InfectionKorea, Republic of
-
University of WashingtonMerck Sharp & Dohme LLCWithdrawnMetastatic Breast Cancer | Triple Negative Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor NegativeUnited States
-
Filipa Lynce, MDMerck Sharp & Dohme LLC; Zentalis PharmaceuticalsNot yet recruitingBreast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast TripleUnited States
-
National University Hospital, SingaporeRecruitingAdvanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast CancersSingapore
-
University of PittsburghCompletedGram Negative OrganismUnited States
-
Wuhan Union Hospital, ChinaNot yet recruitingNegative Surgical Margins
-
Philipps University Marburg Medical CenterUnknownNegative Therapy Expectation
-
Poitiers University HospitalCompletedGram-negative BacteriaFrance
-
Richard BeringerCompletedNegative Behaviour ChangeUnited Kingdom
-
Jiangxi Provincial Cancer HospitalRecruitingTriple-Negative Breast CancerChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingInflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor NegativeUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
Joseph SparanoRecruitingBreast Neoplasms | Breast Diseases | Metastatic Triple Negative Breast CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); American College of Radiology Imaging NetworkActive, not recruitingStage II Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; Gilead SciencesRecruitingBreast Cancer | Triple Negative Breast Cancer | PD-L1 NegativeUnited States
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLC; Cedars-Sinai Medical CenterCompletedBreast Cancer | Metastatic Triple NegativeUnited States
-
Fondazione per la Medicina PersonalizzataUniversity of Roma La SapienzaRecruiting
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingBreast Cancer | Triple-Negative Breast CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteThe Shulas' FoundationRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerUnited States